Introduction
Apoptosis is induced by two distinct cell death pathways, involving either perturbation of mitochondria, resulting in release of proapoptotic mediators, such as cytochrome c, Smac/DIABLO and Omi/HtrA2, or stimulation of cell surface death receptors, often referred to as the intrinsic or extrinsic pathway, respectively. 1, 2 The release of cytochrome c results in the formation of the Apaf-1 apoptosome, which recruits and activates caspase-9 as the apical caspase, which then activates caspase-3 and -7.
3-5 Stimulation of death receptors by CD95 (Fas) or TRAIL (TNF-related apoptosis inducing ligand) results in receptor aggregation and recruitment of FADD/MORT1 (Fasassociated death-domain) and activation of caspase-8 as the apical caspase. 1, 6 Peroxisome-proliferator-activated receptors (PPARs) (a, d and g) induce expression of genes critical to diabetes, obesity, inflammation and cancer. 7, 8 PPARg ligands, such as the triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), have been synthesized as potential anticancer agents partly due to their ability to inhibit cell proliferation and induce apoptosis in many cancer cell lines. [8] [9] [10] CDDO is reported to induce apoptosis by the extrinsic pathway in human myeloid leukemic, osteosarcoma and CLL cells [11] [12] [13] and by the intrinsic pathway in lung cancer cells.
14 As CDDO and derivatives are being developed for the treatment of various cancers including hematological malignancies, it is essential to understand how they induce apoptosis. We demonstrate that CDDO induces apoptosis primarily by the intrinsic pathway in CLL and Jurkat cells.
Materials and methods
Peripheral blood samples from CLL patients, obtained after informed consent and with local ethical committee approval, were purified as previously described 15 except that T cells were removed using anti-CD3 Dynabeads (Dynal, Merseyside, UK). CLL cell purity was assessed by staining with anti-CD19/FITC and anti-CD5/RPE antibodies (Dako, Cambridge, UK) and analyzed by flow cytometry. This method produced an B95% pure population of cells expressing both CD19 and CD5. The purified CLL cells were resuspended in RPMI 1640 medium (4 Â 10 6 /ml) in six or 24-well plates at 371C in an atmosphere of 5% CO 2 and incubated for the indicated times with CDDO (5 mM) or the proteasome inhibitor, MG132 (1 mM) as described. 15, 16 Wild-type, caspase-8-deficient, FADD-deficient and Bcl-x L stably transfected Jurkat cells were cultured as described. 17, 18 CLL or Jurkat cells were pre-treated for 1 h with benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethyl ketone (Z-VAD.fmk) (Enzyme Systems, CA, USA), a caspase inhibitor. Apoptosis was quantified by phosphatidylserine (PS) externalization or loss of mitochondrial membrane potential (c m ) in the presence of propidium iodide (PI) as previously described. 19, 20 CDDO was from Glaxo Smith Kline (Stevenage, UK). Cell samples were prepared and proteins detected by Western blotting. 18 The caspase-9 antibody was from MBL (Nagoya, Japan). After treatment, cells were pelleted, washed with icecold PBS and incubated on ice in buffer (250 mM sucrose, 20 mM Hepes pH 7.4, 5 mM MgCl 2 , 10 mM KCl, 1 mM EDTA, 1 mM EGTA) supplemented with protease inhibitors (Roche, UK) containing 0.05% digitonin for 20 min. Cytosolic (supernatant) and membrane (pellet) fractions were separated by centrifugation at 13 000 g for 10 min. 20 
Results and discussion

CDDO activates the intrinsic pathway in Jurkat cells
To investigate CDDO-induced apoptosis in Jurkat cells, we compared it with etoposide, a DNA topoisomerase II inhibitor, and TRAIL, which induce apoptosis by the intrinsic and extrinsic pathways, respectively. 19 CDDO, etoposide and TRAIL induced apoptosis, assessed by caspase processing, PS externalization and decreases in c m (Figure 1 ). Caspase-3 was processed to its active p19 and p17 forms and caspase-8 to its p43 and p41 forms ( Figure 1 , lanes 5-7, 11 and 13). Z-VAD.fmk inhibited CDDO-and etoposide-induced PS externalization but not their induction of a decrease in c m ( Figure 1, lanes 8-10 and 12 ). These results demonstrated that both CDDO and etoposide induced an initial mitochondrial perturbation. Z-VAD.fmk completely inhibited both CDDO-, etoposide-and TRAILinduced caspase-8 processing and TRAIL-induced caspase-3 and -8 processing (Figure 1, lanes 8-10, 12 and 14) . In TRAILinduced apoptosis, Z-VAD.fmk inhibits caspase-8 processing at the death inducing signaling complex (DISC), 21 so inhibiting processing of all downstream caspases including caspase-3. In marked contrast, Z-VAD.fmk did not prevent CDDO-and etoposide-induced formation of the p20 form of caspase-3 ( Figure 1 , lanes 8-10 and 12), suggesting that CDDO initially activates caspase-9, which cleaves caspase-3 at Asp175 between the large and small subunits forming the p20 fragment. Normally, the autocatalytic activity of caspase-3 removes the Nterminal prodomain to form the p19/p17 fragments, but this is blocked by Z-VAD.fmk so the p20 fragment predominates. Thus with CDDO and etoposide, our data are compatible with active caspase-3, activating caspase-6, which then activates caspase-8 3, 18, 22 and that the inhibition of caspase-3 by Z-VAD.fmk blocks processing of all downstream caspases including caspase-8. Further evidence that caspase-3 was activated prior to caspase-8 was provided by the earlier appearance of processed subunits of cleaved caspase-3 compared to caspase-8 ( Figure 1 , compare lanes 5 and 6), although this difference may be partly due to differing sensitivity of antibodies. Taken together these results support the hypothesis that in Jurkat cells CDDO induces apoptosis primarily by the intrinsic pathway.
If as proposed by others CDDO induces apoptosis by the extrinsic pathway, then it should not induce apoptosis in caspase-8-deficient Jurkat cells. Initially, we determined the sensitivity of caspase-8-deficient Jurkat cells to both etoposide and TRAIL. TRAIL, which induces apoptosis by activation of the extrinsic pathway with caspase-8 as the apical caspase, did not induce apoptosis assessed by processing of caspase-3, PS . In the presence of CDDO alone, caspase-3 was processed primarily to its p19 and p17 forms, whereas in the presence of Z-VAD.fmk it was processed only to its p20 form as the autocatalytic removal of its prodomain was inhibited (Figure 2, lanes 8-10) . Similarly etoposide-induced caspase-3 processing was inhibited at its p20 form in the presence of Z-VAD.fmk (Figure 2, lane 12 ). These data demonstrate that caspase-8 is not required for CDDO-induced apoptosis and that CDDO may induce apoptosis by the intrinsic pathway.
In order to further demonstrate the ability of CDDO to induce apoptosis by the intrinsic pathway, we used FADD-deficient Jurkat cells, FADD being required for the induction of apoptosis by the extrinsic but not the intrinsic pathway. TRAIL did not induce apoptosis in FADD-deficient Jurkat cells, as assessed by processing of caspase-8 or -3, PS externalization or a decrease in c m (Figure 3, lane 13) , whereas etoposide induced apoptosis by all these criteria ( Figure 3, lane 11) . Thus, the FADD-deficient cells were susceptible to apoptosis induced by the intrinsic but not the extrinsic pathway. Exposure of the FADD-deficient Jurkat cells to CDDO resulted in the time-dependent induction of apoptosis as assessed by processing of caspase-3 and -8, PS externalization and a decrease in c m (Figure 3, lanes 5-7) . However, less processing of caspase-8 was observed in the FADD-deficient cells compared to the wild-type Jurkat cells. The effects of Z-VAD.fmk were again very similar to those observed in wild-type Jurkat cells, in particular the inhibition of CDDOand etoposide-induced caspase-3 processing at its p20 form (Figure 3, lanes 9-10 and 12) . These data further demonstrate that CDDO can induce apoptosis primarily by the intrinsic pathway but cannot totally exclude some contribution from the extrinsic pathway. (Figure 4, lane 11) . Similarly, CDDOinduced apoptosis assessed by all these criteria was largely inhibited in Jurkat cells overexpressing Bcl-x L , although a small increase was observed in the percentage of cells with a decreased c m particularly after 42 h (Figure 4, lanes 5-7) . This small increase in the percentage of cells with a low c m is compatible with CDDO inducing an initial perturbation of mitochondria, which would lead to the release of proapoptotic mediators from the mitochondria so resulting in a marked amplification of the apoptotic stimulus.
2 However, as this release is blocked in cells overexpressing Bcl-x L , this results in an inhibition of CDDO-induced apoptosis. In marked contrast, TRAIL induced apoptosis in Jurkat cells overexpressing Bcl-x L as assessed by an increase in PS externalization, a decrease in c m and processing of caspase-3 and -8 ( Figure 4, lane 13) . With TRAIL, a distinctive p20 form of caspase-3 was observed, similar to that seen in death receptor-induced apoptosis in cells overexpressing Bcl-2 or Bcl-x L (Figure 4, lane 13) . 18 Some of this p20/p12 form is inactive because it is inhibited by endogenous X-linked inhibitor-of-apoptosis protein (XIAP). 18 Z-VAD.fmk largely inhibited TRAIL-induced processing of caspase-3 and -8 ( Figure 4, lane 14) . Taken together, these results strongly support the hypothesis that CDDO induces apoptosis in Jurkat cells primarily by the intrinsic pathway.
CDDO activates the intrinsic pathway in CLL cells
CDDO is of potential benefit in the treatment of CLL, as it induces apoptosis in refractory CLL cells and sensitizes some CLL cells to TRAIL. 13 To determine whether the discrepancy with regard to activation of the intrinsic or extrinsic pathway was due to cell-type specificity, we further examined the mechanism of CDDO-induced apoptosis in CLL cells and compared it with MG132, which activates the intrinsic pathway as evidenced by its ability to induce the translocation of Bax, release of cytochrome c, and formation of an B700 kDa Apaf-1 apoptosome. 15, 20 In agreement with our previous results, MG132 induced apoptosis in CLL cells as evidenced by the increase in PS externalization, the decrease in c m and the processing of caspase-3, -8 and -9 ( Figure 5, lane 7) . Pretreatment with Z-VAD.fmk largely inhibited the increase in PS externalization but not the decrease in c m ( Figure 5, lane 8) supporting the suggestion that MG132 initially perturbs mitochondria. CDDO caused a time-dependent induction of apoptosis in CLL cells as evidenced by the increase in PS externalization, the decrease in c m and the processing of caspase-3, -8 and -9 ( Figure 5, lanes 3-5) . Z-VAD.fmk inhibited the CDDO-and MG132-induced processing of caspase-3 primarily at the p20 form ( Figure 5 , lanes 6 and 8) similar to that observed in Jurkat cells (Figure 1, lane 8-10 and 12) . Z-VAD.fmk completely inhibited the CDDO-and MG132-induced processing of caspase-8 ( Figure 5, lanes 6 and 8) . CDDO also induced the processing of caspase-9 to its p35 and p37 fragments and an uncharacterized B25 kDa product, which were only partially inhibited by Z-VAD.fmk ( Figure 5, lanes 3-6) , suggesting that caspase-9 was still active. Processing of caspase-9 at Asp 315 and Asp 330 yielding the p35 and p37 fragments is mediated by Apaf-1 and caspase-3, respectively, and result in an amplification loop. 23, 24 Inhibition of caspase-3 by Z-VAD.fmk inhibits this amplification loop and alters caspase-9 processing. Taken together these results strongly support the hypothesis that CDDO causes an initial perturbation of mitochondria in CLL cells, which results in the release of proapoptotic mediators from the mitochondria and the subsequent activation of caspases with caspase-9 as the apical caspase. 1, 3, 5 In order to confirm this hypothesis, we investigated the release from CLL cells exposed to CDDO of two such proapoptotic molecules from mitochondria, namely cytochrome c and Smac. CDDO induced a time-dependent release of both cytochrome c and Smac from mitochondria, which preceded or accompanied the induction of apoptosis ( Figure 6, lanes 2-4) . Both the CDDO-and MG132-induced release of cytochrome c and Smac were not inhibited by Z-VAD.fmk ( Figure 6, lanes 5 and 7) . These results further support our suggestion that CDDO induces the activation of the intrinsic pathway in CLL cells.
It is unclear why our studies have demonstrated that CDDOinduced apoptosis by the intrinsic pathway, whereas others proposed that it used the extrinsic pathway. [11] [12] [13] Although these differences may be partly due to cell-type specificity they may also result from the methods used. In some studies, caspase activity was assessed using fluorometric substrates, not necessarily specific for the intended caspase. 11, 12 The conclusion that CDDO activated the extrinsic pathway in CLL cells was dependent on data obtained by electroporation into CLL cells, which may have inadvertently introduced experimental artefacts. 13 Although CDDO is a weak PPARg agonist, 8, 9, 25 its ability to induce apoptosis is independent of this activity in both CLL and Jurkat cells. 13, 26 In CLL cells, troglitazone, a potent PPARg agonist failed to induce apoptosis, whereas potent PPARg agonists induce apoptosis in PPARg-negative Jurkat cells. 13, 26 Although our data that CDDO induces apoptosis by the intrinsic pathway in CLL and Jurkat cells is compelling, we cannot totally exclude the involvement of the extrinsic pathway in some cells under certain conditions. This new understanding of the mechanism of CDDO-induced apoptosis is important in the design of more potent analogs, which should be of value in the treatment of some hematological malignancies. CDDO induces the mitochondrial release of cytochrome c and Smac in CLL cells. CLL cells were purified and treated as described in the legend to Figure 5 . Cytosolic and mitochondrial membrane fractions were obtained as described in Materials and methods, resolved by SDS-PAGE and immunoblotted for cytochrome c or Smac.
